Read More

Daré Bioscience Secures $12M In Royalty-Backed Investment Structure; Daré Issued To The Investor A 5-Year Warrant To Purchase An Aggregate Of 5M Shares Of Daré’s Common Stock At An Exercise Price Of $0.3467 Per Share

Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women's health innovation, today announced it has entered into a royalty-backed financing agreement that provides Daré with $5 million at

DARE

Read More

Cannabis Fintech Co. Seeks TSXV Listing As POSaBIT CEO Highlights Potential Benefits

Cannabis payment solutions provider POSaBIT Systems has applied for its common shares to be listed on the TSX Venture Exchange. POSaBIT Systems' CEO and co-founder, Ryan Hamlin, described the application as a continuation of its commitment to increase investment and liquidity options to shareholders. The listing is subject to TSX Venture Exchange review and the fulfilment of all requisite listing and regulatory requirements. The application follows POSaBIT's announcement that it plans to engage in a non-brokered private placement deal of up to 3,107,142 units for gross total proceeds of around CA$870,000 ($652,654). Each unit will be comprised of one common share and 0.88 common share purchase warrants, with each warrant exercisable into one common share in the company at CA$0.40 per warrant share for five years.

CSE:PBIT

Read More

Cyclacel Pharmaceuticals Announces $1.3M Registered Direct Offering Of Of 388,200 Shares At A Price Of $3.315 Per Share And Private Placement Offering Of 7,956 Shares Of Common Stock At A Purchase Price Of $3.315 Per Share

Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC, NASDAQ:CYCCP, ", Cyclacel", or the ", Company", )))), a biopharmaceutical company developing innovative medicines based on cancer cell biology, announced today that it has

CYCC